Close this search box.

Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale

ARTICLE | Emerging Company Profile

Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers

By Karen Tkach Tuzman, Director of Biopharma Intelligence

May 21, 2024 6:31 PM UTC

Updated on May 24, 2024 at 10:06 PM UTC

Editor’s note: This article has been updated to better reflect current understanding of CTSG expression.

Crossbow believes its TCR-mimicking antibodies targeting antigen presentation complexes can scale up the TCR strategy pioneered by Immunocore. As it widens the funnel of tumor-specific targets addressable by bispecific T cell engagers, the company plans to focus on antigens broadly expressed across patient populations. 

Founded in 2021 and incubated by MPM BioImpact, Crossbow Therapeutics Inc. emerged from stealth last year with an $80 million series A round co-led by the founding VC and Pfizer Ventures.